Ownership and insider activity for Reviva Pharmaceuticals Holdings, Inc. (RVPH): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
Price
| Price | $0.49 |
| Market Cap | $6M |
| Exchange | OTC |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 0 | $193 | $8.8M | $29.7M | $18.5M | $23.4M | $13.5M | $14.4M |
| Short-term Investments | $65.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $65.2M | $193 | $8.8M | $31.4M | $18.9M | $23.7M | $14.7M | $15.1M |
| Property, Plant & Equipment | 0 | $591 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $65.2M | $2600 | $8.8M | $31.4M | $18.9M | $23.7M | $15.5M | $15.9M |
| Accounts Payable | 0 | $224543 | $1.0M | $509583 | $3.5M | $3.8M | $6.3M | $3.0M |
| Short-term Debt | 0 | $3.8M | 0 | 0 | 0 | 0 | $458154 | $406875 |
| Total Current Liabilities | 0 | $100102 | $1.3M | $2.3M | $10.0M | $17.2M | $14.6M | $7.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $6.1M | $6.8M | $3.3M | $2.7M | $10.5M | $18.0M | $14.7M | $7.3M |
| Retained Earnings | 0 | -$54.5M | -$58.3M | -$66.8M | -$95.1M | -$134.4M | -$164.3M | -$184.1M |
| Total Equity | 0 | -$6.8M | $5.5M | $28.7M | $8.4M | $5.7M | $812572 | $8.6M |
| Total Debt | 0 | $3.8M | 0 | 0 | 0 | 0 | $458154 | $406875 |
| Net Debt | -$65.2M | $3.8M | -$8.8M | -$29.7M | -$18.5M | -$23.4M | -$13.0M | -$14.0M |
| Working Capital | $65.2M | -$99909 | $7.4M | $29.1M | $9.0M | $6.5M | $81861 | $7.8M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 3.56 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -18.12 |
Profitability
| Return on Equity | -64.39% |
| Return on Invested Capital | -17.05% |
| Return on Assets | -11.58% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANVS · ATNM · BCAB · BTAI · CELU · EVAX · FGEN
Explore sector: Healthcare · Biotechnology
More sections of RVPH: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks